Verastem (VSTM) Net Cash Flow Growth (1y) (2012 - 2026)
Verastem (VSTM) Net Cash Flow Growth (1y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,899.61 Bn | 65,899.33 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.67 Bn | 466.88 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 122.32 Bn | 115.07 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 70.04 Bn | 61.29 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - | - |
| 8 | Argenx Se | 55.93 Bn | 50.74 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.55 Bn | 34.54 Bn | 959.66 Mn | 53.46% |
| 10 | Verastem | 617.27 Mn | 419.45 Mn | 15.90 Mn | -237.17% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -237.17% |
| Dec 31, 2025 | 376.24% |
| Sep 30, 2025 | -161.53% |
| Jun 30, 2025 | 4,492.63% |
| Mar 31, 2025 | 717.25% |
| Dec 31, 2024 | -37.68% |
| Sep 30, 2024 | 134.04% |
| Jun 30, 2024 | -98.81% |
| Mar 31, 2024 | -84.68% |
| Dec 31, 2023 | -392.65% |
| Sep 30, 2023 | -676.46% |
| Jun 30, 2023 | 395.72% |
| Mar 31, 2023 | -9.73% |
| Dec 31, 2022 | -17.28% |
| Sep 30, 2022 | 2,408.36% |
| Jun 30, 2022 | 263.75% |
| Mar 31, 2022 | 178.82% |
| Dec 31, 2021 | 97.78% |
| Sep 30, 2021 | -101.47% |
| Jun 30, 2021 | -6.53% |